{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"disease":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2123274"],"location":["Puerto Rico","United States","Czechia","Thailand","Russia","Netherlands","Sweden","Ireland","Brazil","Slovenia","Chile","Colombia","Hungary","United Kingdom","Spain","India","Lebanon","Canada","Turkey","Belgium","Norway","Finland","Denmark","Italy","Mexico","Israel","Germany"],"study_start_month":["5"],"keyword":["Aflibercept"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen","description":"Primary Objective:\nTo provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants\nSecondary Objective:\nTo document the Health-Related Quality of Life of aflibercept in this participants population","dates":{"creation":"2012-05-15"},"accession":"2123274","cross_references":{"ClinicalTrials___gov":["NCT01571284"],"International Clinical Trials Registry Platform":["U1111-1125-8949"],"EU Clinical Trials Register":["2011-005724-17"]}}